Clinical

Dataset Information

0

Fruquintinib as a Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer


ABSTRACT: This study was a randomized, controled, multicenter, phase II clinical study evaluating the efficacy and safety of fruquintinib as a maintenance therapy following first-line treatment for metastatic colorectal cancer. This study will include the patients with confirmed unresectable metastatic left-sided colon cancer with RAS mutation or right-sided colon cancer who achieved stable disease (SD) or partial response (PR) or complete response (CR) via palliative first-line treatment. It’s expected to include 110 patients and they will be randomly stratified at 2:1 into fruquintinib group and observation group based on whether bevacizumab is used and the primary tumor site, using the Interactive Network Response System (IWRS). The random No. corresponds to the respective patient. The enrollment time is expected to be 18 months, followed up for 24 months.

DISEASE(S): Rectal Neoplasms,Colo-rectal Cancer

PROVIDER: 2332139 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2019-11-25 | PXD012283 | Pride
2019-11-25 | PXD012304 | Pride
2013-08-09 | E-GEOD-48848 | biostudies-arrayexpress
2017-02-01 | GSE93513 | GEO
| 2709221 | ecrin-mdr-crc
2021-11-15 | GSE188711 | GEO
2018-09-19 | GSE120116 | GEO
2019-11-08 | GSE140114 | GEO
| 2749552 | ecrin-mdr-crc
2016-09-26 | GSE64079 | GEO